Clinical trials: Thoracic Tumor
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
- Trial name
- NCT06162221
- Testing
- RMC-6291, RMC-6236, Pembrolizumab
- Where
- 98 sites in United States, Australia and 11 more
- Volunteers
- 616 people
- Sponsor
- Revolution Medicines, Inc.
Small Cell Lung Cancer
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
- Trial name
- NCT03898791
- Testing
- LY3295668 Erbumine
- Where
- 40 sites in United States, Belgium and 6 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
NSCLC, SCLC
Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer…
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
- Trial name
- NCT05546268
- Testing
- Oral MRT-2359
- Where
- 17 sites in United States
- Volunteers
- 174 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Non Small Cell Lung Cancer
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell…
- Trial name
- NCT00735696
- Testing
- Ramucirumab, Paclitaxel, Carboplatin
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
An External Control Arm Study in Non-Small Cell Lung Cancer
A study to create control arms using current and future information in patients with lung cancer.
- Trial name
- NCT07174388
- Where
- 11 sites in United States
- Volunteers
- 650 people
- Sponsor
- N-Power Medicine
Lung Cancer
superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology
The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology.
- Trial name
- NCT03585959
- Testing
- superDimension™ Navigation System Version 7.2
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic - MITG
Lung Cancer
InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology
The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.
- Trial name
- INSPECT (NCT06380361)
- Testing
- BioSpy System
- Where
- 2 sites in Australia, France
- Volunteers
- 30 people
- Sponsor
- Sensome
Non-small Cell Lung Cancer
To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.
It's a Phase Ib/II clinical trial to evaluate the efficacy and safety of TQB3728 tablets in sequential maintenance TQB2450 injection therapy in patients after sequential or concurrent chemoradiation for locally advanced non-small…
- Trial name
- NCT05859373
- Testing
- TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation, TQB2450 injection, sequential or concurrent chemoradiation
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Non-Small-Cell Lung
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy.
- Trial name
- NCT01487174
- Testing
- KD019, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Kadmon Corporation, LLC
Lung Cancer, Cancer of Lung
LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy
A study for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients previously treated with chemotherapy.
- Conditions
- Lung Cancer, Cancer of Lung, Cancer of the Lung, Non-Small Cell Lung Carcinoma
- Trial name
- NCT00328588
- Testing
- YM155
- Where
- 8 sites in Czechia, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- Astellas Pharma Inc
Carcinoma, Non-Small-Cell Lung
A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients
The vaccine contains humanized recombinant antigen (Epithelial Growth Factor) and an adjuvant. The antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation.
- Trial name
- NSCLC (NCT01444118)
- Testing
- Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)
- Where
- United Kingdom
- Sponsor
- Bioven Europe
Small-cell Lung Cancer
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
- Trial name
- DLLEVATE (NCT07218146)
- Testing
- ZL-1310, Investigator's Choice of Therapy
- Where
- 165 sites in United States, Austria and 13 more
- Volunteers
- 480 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Non-Small-Cell Lung Carcinoma
Iressa Versus Docetaxel (Taxotere)
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based…
- Trial name
- NCT00076388
- Testing
- Gefitinib, Docetaxel
- Where
- 162 sites in United States, Argentina and 23 more
- Volunteers
- 1,440 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small Cell Lung
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
- Trial name
- ARTEMIDELung04 (NCT06868277)
- Testing
- Rilvegostomig, Pembrolizumab
- Where
- 304 sites in United States, Argentina and 25 more
- Volunteers
- 830 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
The primary purpose of the study was to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.
- Trial name
- NCT01828112
- Testing
- Ceritinib, Pemetrexed, Docetaxel
- Where
- 97 sites in United States, Belgium and 18 more
- Volunteers
- 231 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy
A multi-center, single-arm. Phase 2 exploratory trial to evaluate the efficacy and safety of HM61713 as the 1st-line anticancer agent in none-small cell lung cancer patients with EGFR mutation
- Trial name
- NCT02444819
- Testing
- HM61713
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Solid Tumors
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
- Trial name
- NCT04418167
- Testing
- JSI-1187, Dabrafenib
- Where
- 7 sites in United States
- Volunteers
- 71 people
- Sponsor
- JS InnoPharm, LLC
Small Cell Lung Cancer
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment.
- Trial name
- NCT06592638
- Testing
- ZG006
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Nonsmall Cell Lung Cancer
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following…
- Trial name
- NCT02981108
- Testing
- HS-10296
- Where
- 10 sites in United States
- Volunteers
- 364 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.